Our Mission
To create value for our customers by accelerating and reducing the costs of R&D through innovative science-based software and consulting solutions that optimize treatment options and improve patient lives.
Celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions!
We are a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide.
Read about our Vision, Mission, and Values
Hosts The Inaugural 2021 MIDD+ Scientific Conference
Simulations Plus hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions. Read More
Releases ADMET Predictor® Version 10.0 (APX™)
Simulations Plus released version 10.0 of its flagship machine learning modeling platform, ADMET Predictor®, The new release is marketed as APX™ on September 2020. Read More
Simulations Plus Raised About $115 Million Underwritten Public Offering of Common Stock
Simulations Plus announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share. Learn More
Lixoft becomes a subsidiary of Simulations Plus
Lixoft becomes a wholly owned subsidiary of Simulations Plus on April, 2020. Lixoft is design software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. Learn More
Grace Fraczkiewicz Celebrates 20 Years of Service
In January 2020, Grace Fraczkiewicz celebrated her 20 years of service with Simulations Plus. Read About her Journey
Robert Fraczkiewicz Celebrates 20 Years of Service
In August of 2018, Robert Fraczkiewicz celebrated his 20 years of service with Simulations Plus. Read About his Journey
Simulations Plus Names Shawn O’Connor as CEO
Shawn M. O’Connor appointed as Chief Executive Officer(CEO) effective from June 26, 2018. Learn More
S+pKa Model Wins SAMPL6 pKa Challenge
Predictions of ionization constants performed by the S+pKa method implemented in ADMET Predictor™ software wins SAMPL6 pKa challenge on February 2018. Learn More
DILIsym Services, Inc. Becomes a Subsidiary of Simulations Plus
DILIsym becomes a wholly owned subsidiary of Simulations Plus. DILIsym is the global leader in the simulation of drug-induced liver injury (“DILI”). Learn More
Jill Fiedler-Kelly Named Fellow of ISoP
Jill Fiedler-Kelly awarded with ISoP Fellowship for her professional excellence and superior impact in pharmacometrics, and for substantial volunteering work for ISoP on October, 2016. Learn More
Simulations Plus Releases PKPlus™ Version 1.0
Simulations Plus released version 1.0 of PKPlus™, its next-generation software for analysis of preclinical and clinical trial data. Learn More
First Commercial Simulx Version
Lixoft released version 1.0 of Simulx, an easy, efficient and flexible application for clinical trail simulations, on December 2014. Learn More
MembranePlus™ Version 1.0 Released
Simulations Plus announced that it has expanded its product portfolio with the release of version 1.0 of its MembranePlus™ simulation software on October 2014. Learn More
Cognigen Corporation Becomes a Subsidiary of Simulations Plus
Cognigen became a wholly-owned subsidiary of Simulations Plus on September 2014. Learn More
Joel and Jill published “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models”
Joel S. Owen and Jill Fiedler-Kelly published a textbook on “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models” on July 2014. Read More
Ted Grasela Awarded With The Gary Neil Prize from ASCPT
Dr. Grasela was awarded the Gary Neil Prize for Innovation in Drug Development from the American Society for Clinical Pharmacology and Therapeutics(ASCPT). Learn More
DILIsym® Version 1A Released
DILIsym® Version 1A was released on January 2012. Learn More
First commercial Monolix® Version 1.0
Monolix® Version 1.0 was released on October 2011. Learn More
Simulations Plus Named to Fortune Small Business FSB 100 List
Simulations Plus has been named to the ninth annual Fortune Small Business FSB 100 list of the fastest-growing small public companies in America. Learn More
DDDPlus™ 1.0 Released
Simulations Plus released version 1.0 of DDDPlus™, a simulation of in vitro dissolution experiments for formulation scientists in the pharmaceutical industry on February 2005. Learn More
ADMET Predictor™ 1.0 Released
Simulations Plus released version 1.0 of ADMET Predictor™, formerly known as QMPRPlus™ on January 2005. Learn More
Simulations Plus Listed on The NASDAQ
In 1999, Simulations Plus listed on the NASDAQ (American Stock Exchange) under the symbol SLP.
GastroPlus® Version 1.0 Released
Simulations Plus releases its flagship PBPK modeling and simulation, GastroPlus®, in July 1998. Learn More
Simulations Plus Incorporated in Lancaster, California
Simulations Plus incorporated in Lancaster, California in July 1996.